These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
590 related articles for article (PubMed ID: 15134549)
1. Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1. Balzarini J Curr Top Med Chem; 2004; 4(9):921-44. PubMed ID: 15134549 [TBL] [Abstract][Full Text] [Related]
2. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. De Clercq E Antiviral Res; 1998 Jun; 38(3):153-79. PubMed ID: 9754886 [TBL] [Abstract][Full Text] [Related]
3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future. De Clercq E Chem Biodivers; 2004 Jan; 1(1):44-64. PubMed ID: 17191775 [TBL] [Abstract][Full Text] [Related]
4. Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. De Clercq E Farmaco; 1999; 54(1-2):26-45. PubMed ID: 10321027 [TBL] [Abstract][Full Text] [Related]
5. Suppression of resistance to drugs targeted to human immunodeficiency virus reverse transcriptase by combination therapy. Balzarini J Biochem Pharmacol; 1999 Jul; 58(1):1-27. PubMed ID: 10403515 [TBL] [Abstract][Full Text] [Related]
6. The effect of NNRTIs on HIV reverse transcriptase dimerization. Tachedjian G; Goff SP Curr Opin Investig Drugs; 2003 Aug; 4(8):966-73. PubMed ID: 14508881 [TBL] [Abstract][Full Text] [Related]
7. Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies. Chen R; Yokoyama M; Sato H; Reilly C; Mansky LM J Virol; 2005 Sep; 79(18):12045-57. PubMed ID: 16140780 [TBL] [Abstract][Full Text] [Related]
11. Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Sharma PL; Nurpeisov V; Hernandez-Santiago B; Beltran T; Schinazi RF Curr Top Med Chem; 2004; 4(9):895-919. PubMed ID: 15134548 [TBL] [Abstract][Full Text] [Related]
12. TSAO compounds: the comprehensive story of a unique family of HIV-1 specific inhibitors of reverse transcriptase. Camarasa MJ; San-Félix A; Velázquez S; Pérez-Pérez MJ; Gago F; Balzarini J Curr Top Med Chem; 2004; 4(9):945-63. PubMed ID: 15134550 [TBL] [Abstract][Full Text] [Related]
18. [Non-nucleoside reverse transcriptase inhibitors]. Joly V; Yeni P Ann Med Interne (Paris); 2000 Jun; 151(4):260-7. PubMed ID: 10922953 [TBL] [Abstract][Full Text] [Related]
19. Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase. Ren J; Stammers DK Virus Res; 2008 Jun; 134(1-2):157-70. PubMed ID: 18313784 [TBL] [Abstract][Full Text] [Related]
20. Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors. Balzarini J; De Clercq E; Carbonez A; Burt V; Kleim JP AIDS Res Hum Retroviruses; 2000 Apr; 16(6):517-28. PubMed ID: 10777142 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]